Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Eli N. Deal"'
Autor:
Amit I. Bery, Eli N. Deal, William B. Call, Aaron P. Hartmann, Sara K. Richter, Amanda C. Bultas
Publikováno v:
Annals of Pharmacotherapy. 53:1207-1213
Background: Little evidence exists for de-escalation of nosocomial pneumonia therapy without positive cultures. Objective: The purpose of this study was to identify potential predictors of treatment failure following de-escalation to a fluoroquinolon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a6b20fa3caaab1451b0b6423c85f8e1
https://doi.org/10.1177/1060028019867114
https://doi.org/10.1177/1060028019867114
Autor:
Heather M. Pautler, Mark Thoelke, Adam V. Meyer, Melissa S. Green, Kevin M. Korenblat, Eli N. Deal
Publikováno v:
Annals of Pharmacotherapy. 50:113-117
Background: The efficacy of vitamin K in lowering an elevated INR in the setting of cirrhosis is not well established. Objectives: The purpose of this investigation is to determine the effect of vitamin K administration on the INR and bleeding events
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6091e39c6ec52586aeea78b575967b96
https://doi.org/10.1177/1060028015617277
https://doi.org/10.1177/1060028015617277
Autor:
Eli N. Deal, Jerrica E. Shuster
Publikováno v:
Journal of the American Society of Nephrology : JASN. 28(7)
It is unclear whether warfarin is protective or harmful in patients with ESRD and atrial fibrillation. This state of equipoise raises the question of whether alternative anticoagulants may have a therapeutic role. We aimed to determine apixaban pharm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e59b93d3bcd939f2fc7b54b8c7d1d857
https://pubmed.ncbi.nlm.nih.gov/28302754
https://pubmed.ncbi.nlm.nih.gov/28302754
Publikováno v:
Annals of Pharmacotherapy. 46:1656-1670
Objective: To evaluate the role of newer agents in the management of atrial fibrillation (AF). Data Sources: EMBASE and MEDLINE were searched (up to June 2012) combining medication names with atrial fibrillation, humans, clinical trials, and pharmaco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02585f75c719395623d769a749184be4
https://doi.org/10.1345/aph.1r155
https://doi.org/10.1345/aph.1r155
Autor:
Ramsey R. Hachem, Roger D. Yusen, Chad A. Witt, J. Iuppa, Eli N. Deal, Amelia K. Sofjan, K. Bennett Bain
Publikováno v:
The Annals of pharmacotherapy. 50(10)
Background: Lung transplant recipients commonly develop complications that lead to anticoagulation. Standard FDA-approved enoxaparin dosing in this population results in a high incidence of above-goal anti-Xa levels, but its association with bleeding
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d8014b637508c6e99ca8adfa098b5e3
https://pubmed.ncbi.nlm.nih.gov/27363845
https://pubmed.ncbi.nlm.nih.gov/27363845
Publikováno v:
Journal of Hospital Medicine. 6:526-529
BACKGROUND: In-hospital insulin administration is associated with many medication errors, but the frequency and reasons for insulin administration errors are poorly described. To document types and frequency of errors related to insulin administratio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::684157617bdef4702c4e7789bab8d46a
https://doi.org/10.1002/jhm.938
https://doi.org/10.1002/jhm.938
Autor:
Eli N. Deal, Lee P. Skrupky, Jennifer R. Smith, Jennifer N. Riney, Richard M. Reichley, James M. Hollands
Publikováno v:
Journal of Thrombosis and Thrombolysis. 32:188-194
Our purpose was to describe anti-Xa levels, dosage requirements, and complications associated with enoxaparin treatment doses in patients with morbid obesity. Inpatients with a BMI40 kg/m(2) at an academic medical center prescribed therapeutic enoxap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31e8904a1606641850bc7bbfae613113
https://doi.org/10.1007/s11239-011-0584-7
https://doi.org/10.1007/s11239-011-0584-7
Autor:
Jennifer R. Smith, Emily Martinez, James M. Hollands, Eli N. Deal, Heather Arnold, Lee P. Skrupky, Scott T. Micek
Publikováno v:
Pharmacotherapy. 30:1229-1238
Study objectives To compare the effectiveness of bivalirudin and argatroban in achieving anticoagulation goals and to compare clinical outcomes assessing the safety and efficacy in patients with known or suspected heparin-induced thrombocytopenia (HI
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73fdba8c40d2ab9e9574459f060dd6be
https://doi.org/10.1592/phco.30.12.1229
https://doi.org/10.1592/phco.30.12.1229
Publikováno v:
Annals of Pharmacotherapy. 42:1507-1510
Objective: To report the development of neutropenia in a patient after almost 8 years of being stabilized on delayed-release divalproex sodium (DVPX). Case Summary: A 45-year-old man had been maintained on DVPX for nearly 8 years, with serum valproic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::813f6f81591f5d132eb49287e54df4a1
https://doi.org/10.1345/aph.1l239
https://doi.org/10.1345/aph.1l239
Publikováno v:
Clinical Therapeutics. 30:787-799
Background: Evidence exploring the use of corticosteroids for acute respiratory distress syndrome (ARDS) has targeted various stages of disease progression, from preventing ARDS in high-risk patients to halting disease evolution once ARDS has develop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47f3c2bd29a4644a92345bab067dc271
https://doi.org/10.1016/j.clinthera.2008.05.012
https://doi.org/10.1016/j.clinthera.2008.05.012